TY - JOUR
T1 - Sipuleucel-T and androgen receptor-directed therapy for castration-resistant prostate cancer
T2 - A meta-analysis
AU - Yi, Renliang
AU - Chen, Baoxin
AU - Duan, Peng
AU - Zheng, Chanjiao
AU - Shen, Huanyu
AU - Liu, Qun
AU - Yuan, Chen
AU - Ou, Weilin
AU - Zhou, Zhiheng
N1 - Publisher Copyright:
© 2016 Renliang Yi et al.
PY - 2016
Y1 - 2016
N2 - New treatments, such as sipuleucel-T and androgen receptor-(AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p>0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p>0.05).
AB - New treatments, such as sipuleucel-T and androgen receptor-(AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p>0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p>0.05).
UR - http://www.scopus.com/inward/record.url?scp=85008970496&partnerID=8YFLogxK
U2 - 10.1155/2016/4543861
DO - 10.1155/2016/4543861
M3 - Review article
C2 - 28058266
AN - SCOPUS:85008970496
SN - 2314-8861
VL - 2016
JO - Journal of Immunology Research
JF - Journal of Immunology Research
M1 - 4543861
ER -
